Company: NCEL
Filing Date: 2025-09-25
Form Type: F-1
Source: 0001213900-25-091697
Chunk: 132

Company: NewcelX Ltd.
Filing Date: 2025-09-25
Form: F-1
Chunk 132
---
 the opinion of its counsel   
 the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification 
 by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.                          |

| (c) | The undersigned registrant hereby 
 undertakes that:                  |

| (1) | For purposes of determining                                                                                                            
 any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this registration 
 statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4),  
 or 497(h) under the Securities Act shall be deemed to be part of this prospectus as of the time it was declared effective.             |

| (2) | For the purpose of determining                                                                                                            
 any liability under the Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed to be    
 a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed 
 to be the initial bona fide offering thereof.                                                                                             |

<div align='center'>II-6

SIGNATURES</div>

Pursuant to the requirements
of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements
for filing on Form F-1 and has duly caused this prospectus on Form F-1 to be signed on its behalf by the undersigned, thereunto duly authorized,
in Zurich, Switzerland, on September 25, 2025.

| NLS PHARMACEUTICS LTD. |                         |
| By:                    | /s/ Alexander Zwyer     |
|                        | Alexander Zwyer         |
|                        | Chief Executive Officer |

<div align='center'>POWER OF ATTORNEY</div>

The undersigned officers and
directors of NLS Pharmaceutics Ltd. hereby constitute and appoint Alexander Zwyer as our true and lawful attorney-in-fact and agent to
take any actions to enable the Company to comply with the Securities Act, and any rules, regulations and requirements of the SEC, in connection
with this prospectus on Form F-1, including the power and authority to sign for us in our names in the capacities indicated below any
and all further amendments to this prospectus and